Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Unique Immediate Postoperative Management of Crohn’s Disease in a Patient with Autoimmune Hepatitis-Like Drug-Induced Liver Injury from Infliximab Requiring Liver Transplantation

Derek J. Estes*, Winnie Szeto, Michael Kingsley, Julio Cesar Poveda, Thiago Beduschi, Amar R. Deshpande

Division of Gastroenterology and Hepatology, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USA

Abstract: Drug-induced autoimmune hepatitis (DI-AIH) is a poorly defined, underreported liver disorder. This report describes a rare case of anti-TNF DI-AIH in a patient with Crohn’s disease resulting in acute liver failure requiring orthotopic liver transplantation in which a novel technique of leveraging a delayed abdominal fascial closure to perform ileocolonic anastomotic revision was used.

Keywords: Crohn’s disease, drug-induced liver injury (DILI), inflammatory bowel disease (IBD), infliximab, orthotopic liver transplantation

Received September 24, 2019; Revised November 06, 2019; Accepted November 14, 2019

Citation: Derek J. Estes, Winnie Szeto, Michael Kingsley, Julio Cesar Poveda, Thiago Beduschi, Amar R. Deshpande, Unique Immediate Postoperative Management of Crohn’s Disease in a Patient with Autoimmune Hepatitis-Like Drug-Induced Liver Injury from Infliximab Requiring Liver Transplantation. American Journal of Medical Case Reports, 8 (1). 11-13. January 2020. doi:10.12691/ajmcr-8-1-3

1. Introduction

Drug-induced autoimmune hepatitis (DI-AIH) is a poorly defined, underreported liver disorder. It comprises acute and chronic liver injury accompanied by the development of autoantibodies, a hepatocellular pattern of serum enzyme elevation and liver biopsy features suggestive of idiopathic autoimmune hepatitis (AIH). Unlike AIH, it typically resolves completely once the medication is withdrawn; recovery can be slow and may require a limited course of corticosteroid therapy [1].

Cases of significant liver disease associated with infliximab (IFX) treatment have been reported in patients with rheumatoid arthritis, Crohn’s disease (CD), and psoriatic arthritis [2]. This report describes a rare case of anti-TNF DI-AIH in a patient with CD resulting in acute liver failure requiring orthotopic liver transplantation (OLT) in which a novel technique of leveraging a delayed abdominal fascial closure to perform ileocolonic anastomotic revision was used.

2. Case Report

A 45-year-old female with longstanding ileocolonic CD status post four small bowel resections had previously failed adalimumab based on persistent symptoms and a nontraversable ileocolonic inflammatory anastomotic stricture on colonoscopy with limited neo-terminal ileal disease on radiographic imaging. She started IFX with minimal improvement, and five months later she was admitted to an outside hospital with 3 days of abdominal pain and hematochezia thought to be secondary to a CD flare. On admission she was noted to have markedly elevated liver chemistries (AST 1048 IU/l, ALT 1222 IU/l, bilirubin 4.9 mg/dL); three months prior to presentation after IFX induction, liver chemistries were normal (AST 17 IU/l, ALT 10 IU/l, total bilirubin 0.4 mg/dL).

Over the next week, aminotransferases remained elevated with rising bilirubin and INR without encephalopathy or renal failure; she was then transferred to our center for further management. Hepatic imaging had no mass lesion, hepatic/portal vein flow abnormalities, or biliary dilation. Toxin assays were negative (including acetaminophen), as was an infectious workup (viral hepatitis A-E, cytomegalovirus, herpes simplex virus, Epstein-Barr virus, varicella zoster virus). Ceruloplasmin was normal, as were smooth muscle and liver kidney microsomal type 1 antibodies (<20.0), but ANA (speckled, 1:320), dsDNA antibody (133 IU/mL), and serum IgG (1938 mg/dl) were noted to be mild to moderately elevated with normal serum IgM. She had no reported hypotension in her previous hospital course. As her bilirubin and INR continued to climb to peaks of 21 mg/dL and 3.3 mg/dL respectively, with the development of hepatic encephalopathy (confusion and lethargy), a workup for liver transplantation was under-taken. N-acetylcysteine was given empirically. Hepatic and portal venous pressures and gradient were normal on transjugular liver biopsy, which revealed marked inflammatory infiltrate and parenchymal collapse with both necroinflammatory and cholestatic patterns of injury most consistent with drug-induced liver injury (DILI); there was no advanced fibrosis (Figure 1 & Figure 2). On hospital day 15, with a biologic MELD of 31, she underwent OLT; explant histology was consistent with DI-AIH. Skin was closed but fascial closure was delayed due to large donor liver, bowel edema, and prolonged operating time.

Four days later the patient returned to the operating room for a delayed abdominal fascial closure. To avoid need for repeat surgical intervention soon after OLT, a decision was made to use her delayed fascial closure as an opportunity to perform a resection of her tight ileocolonic anastomotic stricture. Fifteen centimeters of neo-terminal ileum in addition to the anastomotic stricture was resected with primary ileocolonic anastomosis followed by abdominal fascial closure; pathology was consistent with CD.

Figure 1. Portal tract inflammatory infiltration with abundant plasma cells, lymphocytes, and eosinophils with interface hepatitis

Figure 2. Portal tract inflammatory infiltration with abundant plasma cells, lymphocytes, and eosinophils with interface hepatitis

3. Discussion

IFX is a human-murine chimeric antibody directed against tumor necrosis factor alpha with well-established efficacy in the treatment of several autoimmune diseases [3]. Since the introduction of IFX in 1999, twenty-eight cases of DILI related to it have been described in the English literature [4]. As in our case, a number of these patients have been found to have positive ANA and dsDNA [4]. In a recent study by Shelton et al. looking at ALT elevation in 1753 IBD patients initiating anti-TNF therapy, 6% developed new onset ALT elevation within 5 months of initiation of anti-TNF therapy [5].

The role of corticosteroids in modifying outcome continues to be controversial. A study by Yeoman et al. characterized a cohort of patients with acute severe AIH (AS-AIH); although untreated patients had a higher MELD score at presentation (34 vs 28, p=0.01), there was no difference in sepsis or mortality observed between corticosteroid untreated or treated patients (11% vs. 26% [p=0.6] and 22% vs. 17% [p=0.99] respectively) [6]. We did not institute corticosteroid therapy in our patient given the timing of her presentation to our institution and her rapid decompensation. N-acetylcysteine (NAC) was given empirically as studies have shown that treatment with NAC may benefit patients with non-acetaminophen related acute liver failure. In 2009, Lee WM and his colleagues demonstrated that transplant-free survival was better for NAC patients (40%) than for those given placebo (27%, p=0.043) [7]. This improvement may be via improved systemic hemodynamics, tissue oxygen delivery, or other favorable effects on the injured liver [7,8].

Table 1. Cases of Fulminant Liver Failure Associated with Infliximab Treatment Resulting in Hepatic Transplantation

Only 4 other documented cases of IFX-related acute liver failure have been reported (Table 1) [2,3,9]. This is the first reported case in the literature using the delayed fascial closure of the abdominal wall after liver transplantation as an opportunity for surgical management of CD.

Liver edema can result in a tight primary abdominal wound closure resulting in various complications including wound dehiscence, partial liver necrosis, intra-abdominal hypertension, subcapsular hepatic necrosis, vascular compression or thrombosis, and abdominal compartment syndrome [10]. In order to prevent these complications, our surgical transplant team used a delayed abdominal fascial closure technique. Primary abdominal wall closure is delayed and a temporary prosthetic closure is performed instead. By using a prosthetic closure, the surgical team is able to avoid the risk of infection and minimize fluid loss while allowing time for the bowel and liver edema to improve in order to maximize the chances of a successful abdominal wall closure.

The delayed primary closure of liver transplantation has been reported in the pediatric population and has been shown to be safe with no significant long-term is-sues and was not associated with higher incidence of wound related complications [10,11]. Because the patient had a tight anastomotic stricture and focal distal ileal inflammation for which medical treatment for CD would need to be delayed, and since she would likely need surgical anastomotic revision despite optimal medical therapy, we leveraged our center’s delayed fascial closure technique to perform concomitant anastomotic revision. Resection at the time of her delayed fascial closure, instead of at the time of her initial liver transplantation procedure, allowed us to optimize her coagulation parameters, temperature, and blood supply to a new anastomotic connection; these factors might have been comprised at the time of her initial liver transplantation, which required more than five hours of operating time.

Here we report the first case of IFX causing DI-AIH that led to OLT in a CD patient and the first case of using a delayed fascial closure technique to be able to safely perform other surgeries in the peri-OLT period for management of CD.

Acknowledgements and Statement of Competing Interests

The authors of this manuscript have no acknowledgments and no competing interests.

List of Abbreviations

DI-AIH Drug-induced autoimmune hepatitis, AIH autoimmune hepatitis, IFX infliximab, CD Crohn’s disease, OLT Orthotopic liver transplantation, DILI Drug-induced liver injury, AS-AIH Acute severe autoimmune hepatitis, NAC N-acetylcysteine.

References

[1]   | Overview Infliximab. http://livertox.nih.gov/Infliximab.htm.
[2]   | Tobon GJ, Canas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol, 2007; 26: 578-581.
[3]   | Rowe BW, Boris G, Corey T, et al. Fulminant hepatic failure necessitating transplantation following the initiation of infliximab therapy: a cautionary tale times two. Transpl Int, 2013; 26: e110-e112.
[4]   | Colina F, Molero A, Begoña C, et al. Infliximab-related hepatitis: A case study and literature review. Dig Dis Sci, 2013; 58: 3362-3367.
[5]   | Shelton E, Chaudrey K, Khalili H, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Ther, 2015; 10: 972-979.
[6]   | Yeoman AD, Westbrook RH, Zen Y et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol, 2014 Oct; 61(4): 876-882.
[7]   | Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology, 2009; 137(3):856-864.
[8]   | Sales I, Dzierba AL, Smithburger PL, et al. Use of acetylcysteine for non-acetaminophen-induced acute liver failure. Ann Hepatol, 2013; 12(1):6-10.
[9]   | Michel M, Cristophe D, Cristophe H, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol, 2003; 30(7):1624-1625.
[10]   | de Ville de GJ, Struye de SY, Reding R, et al. Delayed primary closure of the abdominal wall after cadaveric and living related donor liver graft transplantation in children: a safe and useful technique. Transpl Int, 1998; 11(2): 117-122.
[11]   | Ziaziaris WA, Darani A, Holland AJ, et al. Delayed primary closure and the incidence of surgical complications in pediatric liver transplant recipients. J Pediatr Surg, 2015; 50(12):2137-40.